Visão geral da empresa
A clinical-stage biotechnology entity, Seres Therapeutics, Inc., is dedicated to the development of biotherapeutics designed to address serious diseases through innovative therapeutic modalities. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high degree of research intensity and regulatory scrutiny in its product development lifecycle. On a quantitative scale, the organization employs 66 individuals and maintains a market capitalization of $83.50M, while reporting an annual revenue of $789,000. These valuation and revenue metrics collectively indicate that the company occupies a niche position within the market, characterized by a relatively small market cap that reflects its early-stage clinical status and limited revenue generation from commercial sales.
Saúde financeira
The company reports a trailing twelve-month revenue of $789,000, a net income of $5.70M, and an EBITDA of $-89,838,000. The substantial gap between the minimal revenue figure and the positive net income reveals a highly distorted cost structure where non-operating gains or accounting adjustments have significantly inflated reported profitability relative to actual cash-generating operations. Free cash flow stands at $-54,955,876, indicating a significant cash outflow that suggests the company currently lacks the financial flexibility to fund operations internally and likely relies on external capital markets for liquidity. The gross margin is recorded at 0.0%, while the operating margin is -4424.0% and the profit margin is 721.9%; these divergent figures highlight extreme volatility in reported profitability, where the profit margin metric is mathematically inflated by the low revenue base against a fixed or high cost structure. Total cash on hand is $45.77M, which is insufficient to cover total debt of $82.97M, and the debt-to-equity ratio of 187.63% further confirms a highly leveraged balance sheet position. The current ratio of 2.56 indicates that the company possesses liquid assets sufficient to cover short-term obligations more than twice over, suggesting adequate short-term liquidity despite the long-term debt burden. Return on Equity is 19.6% and Return on Assets is -42.3%, metrics that reveal a complex management effectiveness profile where equity returns are positive likely due to leverage effects, while asset returns remain negative due to the heavy debt load and operational inefficiencies.
Avaliação de valorização
The trailing P/E ratio is 13.61, whereas the forward P/E is -0.95, a discrepancy that implies the market does not anticipate immediate earnings recovery and suggests expected earnings will be negative in the coming fiscal period. The price-to-book ratio stands at 1.88, indicating that the market values the company at a premium of 88% over its tangible book value, potentially reflecting optimism regarding future asset appreciation or intangible value not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 105.83 and an EV/EBITDA of -1.34 suggest that traditional earnings-based models are inappropriate for this asset, pointing instead to a valuation heavily weighted on sales potential or speculative future clinical outcomes. The stock has traded between a 52-week high of $29.98 and a 52-week low of $6.53, providing a volatility range within which the current price must be contextualized relative to recent market sentiment. With a beta of 0.26, the stock exhibits low price volatility relative to the broader market, moving significantly less than the market index and suggesting lower systemic risk but also lower potential upside in bullish market conditions.
Growth & Income
The company reports no available revenue growth or earnings growth rates year-over-year, which precludes a direct comparison of earnings speed against revenue expansion in the traditional sense for this specific reporting period. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders. Consequently, the overall growth and income profile is defined entirely by capital appreciation potential rather than income generation, relying on successful clinical trials to drive future valuation expansion. The absence of dividend payments aligns with the clinical-stage nature of the business, where capital preservation and reinvestment are prioritized over shareholder income distributions.